{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:25:26Z","timestamp":1792027526810,"version":"4.4.0"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T00:00:00Z","timestamp":1572825600000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Oritavancin (ORI) is a long-acting lipoglycopeptide indicated for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSIs) caused or suspected to be caused by susceptible Gram-positive (GP) pathogens.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data collected from a retrospective observational program (2014\u20132017), Clinical and Historic Registry and Orbactiv Medical Evaluation (CHROME), describe the utilization, outcomes, and adverse events (AEs) associated with ORI in 440 patients treated at 26 US sites for ABSSSI and other GP infections.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Clinical success in evaluable patients receiving at least 1 dose of oritavancin was 88.1% (386\/438). In a subgroup of patients who received ORI for skin and soft tissue infections (n = 401) and bacteremia (n = 7), clinical success was achieved in 89.0% and 100%, respectively. A cohort of 32 patients received 2\u201310 ORI doses separated by no more than 14 days for complicated GP infections. Clinical success was observed in 30 of 32 patients (93.8%), including 10 of 11 (90.9%) patients with bone and joint infections and 7 of 8 (87.5%) patients with osteomyelitis. In the safety evaluable population, the overall rate of AEs was 6.6%.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>We describe results from a real-world program that includes the largest multicenter, retrospective, observational study in patients who received at least 1 dose of ORI for the treatment of GP infections. This study confirms that ORI is an effective, well-tolerated antibiotic used in single and multiple doses for the treatment of ABSSSIs and complicated GP infections.<\/jats:p><\/jats:sec>","DOI":"10.1093\/ofid\/ofz479","type":"journal-article","created":{"date-parts":[[2019,11,4]],"date-time":"2019-11-04T17:14:05Z","timestamp":1572887645000},"source":"Crossref","is-referenced-by-count":44,"title":["The CHROME Study, a Real-world Experience of Single- and Multiple-Dose Oritavancin for Treatment of Gram-Positive Infections"],"prefix":"10.1093","volume":"6","author":[{"given":"Mark","family":"Redell","sequence":"first","affiliation":[{"name":"Melinta Therapeutics, Morristown, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Sierra-Hoffman","sequence":"additional","affiliation":[{"name":"Director of Research, Texas A&M affiliated Detar Family Medicine Program & College of Medicine, Victoria, Texas, USA"},{"name":"Texas A&M University, Bryan, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maha","family":"Assi","sequence":"additional","affiliation":[{"name":"IDC Clinical Research, Wichita, Kansas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markian","family":"Bochan","sequence":"additional","affiliation":[{"name":"Infectious Diseases of Indiana, Indianapolis, Indiana, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Chansolme","sequence":"additional","affiliation":[{"name":"Infectious Disease Consultants of Oklahoma City, Oklahoma City, Oklahoma, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anurag","family":"Gandhi","sequence":"additional","affiliation":[{"name":"Birmingham Infectious Disease and Infusion, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen","family":"Sheridan","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Physicians, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivan","family":"Soosaipillai","sequence":"additional","affiliation":[{"name":"Infectious Disease Associates of North Central Florida, Ocala, Florida, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Walsh","sequence":"additional","affiliation":[{"name":"Allegheny Health Network, Pittsburgh, Pennsylvania, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Massey","sequence":"additional","affiliation":[{"name":"Melinta Therapeutics, Morristown, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,11,4]]},"reference":[{"issue":"1","key":"2019121010470917800_CIT0001","first-page":"1","article-title":"Antibiotic development and clinical utilization; a reality check","volume":"2","author":"Van Hise","year":"2019","journal-title":"Ann Microbiol Immunol"},{"key":"2019121010470917800_CIT0002","volume-title":"Prescribing Information \u2013 ORBACTIV (Oritavancin) for Injection","author":"Melinta Therapeutics"},{"issue":"23","key":"2019121010470917800_CIT0003","doi-asserted-by":"crossref","first-page":"2180","DOI":"10.1056\/NEJMoa1310422","article-title":"Single-dose oritavancin in the treatment of acute bacterial skin infections","volume":"370","author":"Corey","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"2019121010470917800_CIT0004","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1093\/cid\/ciu778","article-title":"Single-dose oritavancin versus 7\u201310 days of vancomycin in the treatment of gram-positive acute bacterial skin and skin structure infections: the SOLO II noninferiority study","volume":"60","author":"Corey","year":"2015","journal-title":"Clin Infect Dis"},{"key":"2019121010470917800_CIT0005","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1016\/j.ijantimicag.2016.07.019","article-title":"Pooled analysis of single-dose oritavancin in the treatment of acute bacterial skin and skin-structure infections caused by Gram-positive pathogens, including a large patient subset with methicillin-resistant Staphylococcus aureus","volume":"48","author":"Corey","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"23","key":"2019121010470917800_CIT0006","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","article-title":"Once-weekly dalbavancin versus daily conventional therapy for skin infection","volume":"370","author":"Boucher","year":"2014","journal-title":"N Engl J Med"},{"issue":"5","key":"2019121010470917800_CIT0007","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/cid\/civ982","article-title":"A randomized clinical trial of single-dose dalbavancin versus weekly dalbavancin for the treatment of acute bacterial skin and skin structure infection","volume":"62","author":"Dunne","year":"2016","journal-title":"Clin Infect Dis"},{"issue":"7","key":"2019121010470917800_CIT0008","doi-asserted-by":"crossref","first-page":"ofz274","DOI":"10.1093\/ofid\/ofz274","article-title":"Long-acting lipoglycopeptides: \u201clineless antibiotics\u201d for serious infections in persons who use drugs","volume":"6","author":"Morrisette","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2019121010470917800_CIT0009","doi-asserted-by":"crossref","first-page":"77","DOI":"10.2174\/1871526517666161108130148","article-title":"Use of oritavancin (novel new lipoglycopeptide) in the treatment of prosthetic joint infections (PJI): a possible alternative novel approach to a difficult problem","volume":"17","author":"Antony","year":"2017","journal-title":"Infect Disord Drug Targets"},{"key":"2019121010470917800_CIT0010","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofv156","article-title":"Prolonged use of oritavancin for vancomycin-resistant Enterococcus faecium prosthetic valve endocarditis","volume":"2","author":"Johnson","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"2019121010470917800_CIT0011","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s40121-017-0156-z","article-title":"Real-world experience with oritavancin therapy in invasive Gram-positive infections","volume":"6","author":"Stewart","year":"2017","journal-title":"Infect Dis Ther"},{"issue":"1","key":"2019121010470917800_CIT0012","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/phar.2057","article-title":"Multiple-dose oritavancin evaluation in a retrospective cohort of patients with complicated infections","volume":"38","author":"Schulz","year":"2018","journal-title":"Pharmacotherapy"},{"issue":"8","key":"2019121010470917800_CIT0013","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1002\/phar.1957","article-title":"Successful treatment of methicillin-susceptible Staphylococcus aureus osteomyelitis with oritavancin","volume":"37","author":"Delaportas","year":"2017","journal-title":"Pharmacotherapy"},{"key":"2019121010470917800_CIT0014","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1097\/IPC.0000000000000517","article-title":"Oritavancin for the treatment of daptomycin nonsusceptible vancomycin-resistant Enterococci","volume":"26","author":"Foster","year":"2018","journal-title":"Infect Dis Clin Pract"},{"key":"2019121010470917800_CIT0015","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ijantimicag.2018.11.023","article-title":"Treatment of chronic osteomyelitis with multidose oritavancin: a case series and literature review","volume":"53","author":"Chastain","year":"2019","journal-title":"Internat J Antimicrob Agents"},{"key":"2019121010470917800_CIT0016","doi-asserted-by":"crossref","first-page":"e02622","DOI":"10.1128\/AAC.02622-18","article-title":"Treatment of multidrug-resistant vancomycin-resistant Enterococcus faecium hardware-associated vertebral osteomyelitis with oritavancin plus ampicillin","volume":"63","author":"Dahesh","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"2019121010470917800_CIT0017","doi-asserted-by":"crossref","first-page":"ofy051","DOI":"10.1093\/ofid\/ofy051","article-title":"A real-world patient registry for oritavancin demonstrates efficacy and safety consistent with the SOLO phase 3 program","volume":"5","author":"Redell","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"2019121010470917800_CIT0018","doi-asserted-by":"crossref","first-page":"e01919","DOI":"10.1128\/AAC.01919-17","article-title":"Single intravenous dose of oritavancin for treatment of acute skin and skin structure infections caused by Gram-positive bacteria: summary of safety analysis from the phase 3 SOLO studies","volume":"62","author":"Corey","year":"2018","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofz479\/30351924\/ofz479.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/11\/ofz479\/31484071\/ofz479.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/6\/11\/ofz479\/31484071\/ofz479.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,27]],"date-time":"2021-01-27T03:26:48Z","timestamp":1611718008000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofz479\/5612294"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,1]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofz479","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11]]},"published":{"date-parts":[[2019,11,1]]},"article-number":"ofz479"}}